CytRx Corporation (NASDAQ:CYTR) Plans To Avoid Delisting From NASDAQ

CytRx Corporation (NASDAQ:CYTR) reported that it has submitted a preliminary proxy statement with the SEC pertaining to a planned special meeting of shareholders to authorize the company’s Board to follow a reverse stock split of the firm’s common stock, if seen necessary. It may allow the firm to regain compliance with NASDAQ’s $1 minimum bid […]

CytRx Corporation (NASDAQ:CYTR) Has Plans Underway To Reshape The Clinical And Regulatory Executive Team

CytRx Corporation (NASDAQ:CYTR) has today made the much awaited announcement. It revealed that Shanta Chawla, who had been serving the company in the capacity of the Vice President of Clinical Development since 2014 will be given a promotion. The promotion will have him serve as the new Senior Vice President of Drug Development. He will […]

Stocks To Watch: Amedica Corporation (NASDAQ:AMDA),, Inc. (NYSE:CRM), CytRx Corporation (NASDAQ:CYTR)

Boston, MA 10/14/2014 (wallstreetpr) – Silicon nitride ceramics equipment and materials manufacturer Amedica Corporation (NASDAQ:AMDA), announced on 13th October that company’s former Chairman of the Board of Directors, Max E. Link, Ph.D., had passed away. Dr. Link was said to be 74 years of age at the time of his unexpected death. Amedica Corporation (NASDAQ:AMDA) […]

Winning Cancer Drug Drives CytRx Corporation (NASDAQ:CYTR) By 50%

Boston, MA 12/13/2013 (wallstreetpr) –  The success of CytRx Corporation (NASDAQ:CYTR) latest cancer drug – Aldoxorubicin – has driven stock prices by over 50%. The drug has just proved to be more effective than the more commonly used drug doxorubicin, as Aldoxorubicin prevented growth of tumorous soft-tissue more effectively. Chemotherapy is the most used treatment for […]

CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial

Boston, MA 10/01/2013 (wallstreetpr) – On September 30, CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address soft tissue sarcoma. The results showed that patients treated with target drug “aldoxorubicin” had responded better to treatment by over 22% as compared to their responses when treated by existing […]